Literature DB >> 4564405

Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

J W Murphy, G C Cozad.   

Abstract

Numerous studies have suggested that cryptococcal capsular polysaccharide could induce an immunological paralysis. To investigate this possibility, mice were given various concentrations of purified cryptococcal polysaccharide and then 14 days later were challenge-immunized with the same material in Freund's incomplete adjuvant. Anticryptococcal agglutinin titers were determined at various periods after polysaccharide treatment and after challenge immunization. At the same periods the hemolytic plaque technique was used to determine the number of spleen cells capable of producing antibody against cryptococcal polysaccharide. The data indicated that there was a transitory immune response which preceded tolerance induction. In animals given the largest doses of polysaccharide, "in vivo" neutralization was responsible for low serum agglutinin titers during the transitory response. The capsular polysaccharide was considered to have induced immunological unresponsiveness at the highest concentration, because challenge immunization did not stimulate an increase in the number of plaque-forming cells (PFC). A sixfold increase in numbers of PFC was found in animals injected initially with the lowest concentration of polysaccharide. These results support the idea that tolerance was due to terminal differentiation without proliferation of the immunocompetent cells. The central failure of the immune mechanism which was apparent in the paralyzed mice was temporary under the conditions of this experiment.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4564405      PMCID: PMC422459          DOI: 10.1128/iai.5.6.896-901.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Active immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  J Infect Dis       Date:  1958 May-Jun       Impact factor: 5.226

2.  The antigenic compostion of Cryptococcus neoformans. IV. The use of paper chromatography for following purification of the capsular polysaccharide.

Authors:  E E EVANS; R J THERIAULT
Journal:  J Bacteriol       Date:  1953-05       Impact factor: 3.490

3.  The antigenic composition of Cryptococcus neoformans. II. Serologic studies with the capsular polysaccharide.

Authors:  E E EVANS; J F KESSEL
Journal:  J Immunol       Date:  1951-08       Impact factor: 5.422

4.  A comparison of the immunogenicity of weakly encapsulated and of strongly encapsulated strains of Cryptococcus neoformans (Torula histolytica).

Authors:  J M NEILL; I ABRAHAMS; C E KAPROS
Journal:  J Bacteriol       Date:  1950-02       Impact factor: 3.490

Review 5.  Developmental aspects of immunity.

Authors:  J Sterzl; A M Silverstein
Journal:  Adv Immunol       Date:  1967       Impact factor: 3.543

6.  Sequence of events in mice early in immunologic paralysis by pneumococcal polysaccharide.

Authors:  P Matangkasombut; C V Seastone
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

7.  Immunologic tolerance to Escherichia coli somatic antigen assessed by bacteriolytic and hemolytic plaque assays.

Authors:  J L Allen; H Friedman
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Immunological tolerance induced by cyclophosphamide assayed by plaque spleen cell method.

Authors:  A C Aisenberg; B Wilkes
Journal:  Nature       Date:  1967-02-04       Impact factor: 49.962

9.  Immunological unresponsiveness in rabbits produced by neonatal injection of defined antigens.

Authors:  R T SMITH; R A BRIDGES
Journal:  J Exp Med       Date:  1958-08-01       Impact factor: 14.307

10.  Studies on the induction of immunological unresponsiveness to pneumococcal polysaccharide in mice.

Authors:  G W Siskind; J G Howard
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

  10 in total
  117 in total

1.  Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction.

Authors:  K L Buchanan; J W Murphy
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation.

Authors:  P L Fidel; J W Murphy
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

3.  In vitro binding of natural killer cells to Cryptococcus neoformans targets.

Authors:  N Nabavi; J W Murphy
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

4.  In vitro interactions of immune lymphocytes and Cryptococcus neoformans.

Authors:  P Y Fung; J W Murphy
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

Review 5.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

6.  Cryptococcal capsular polysaccharide clearance in nonimmune mice.

Authors:  H G Muchmore; E N Scott; F G Felton; R A Fromtling
Journal:  Mycopathologia       Date:  1982-04-23       Impact factor: 2.574

7.  Decreased resistance to primary intravenous Cryptococcus neoformans infection in aged mice despite adequate resistance to intravenous rechallenge.

Authors:  K M Aguirre; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection.

Authors:  L K Cauley; J W Murphy
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

10.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.